MVP (mitomycin, vinblastine, and progesterone): a second-line regimen in ovarian cancer with a high incidence of pulmonary toxicity.
Thirteen patients with epithelial ovarian cancer refractory to primary combination chemotherapy regimens were treated with a three-drug combination called MVP: mitomycin, vinblastine, and progesterone. None of the patients had an objective response to therapy. Five of the 13 patients (39%) developed signs and symptoms consistent with drug-induced pulmonary toxicity following therapy with MVP and histologic confirmation was obtained in two patients. Mitomycin and vinblastine therapy in heavily treated patients with ovarian cancer may be associated with a higher risk of pulmonary toxicity than that previously reported for patients with other tumors.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000633:toxicity; D000971:Antineoplastic Combined Chemotherapy Protocols; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008168:Lung / Q000187:drug effects*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011374:Progesterone / Q000008:administration & dosage* / Q000009:adverse effects; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D008937:Mitomycins; D011374:Progesterone; D016685:Mitomycin; D014747:Vinblastine